Pharma-Bio Serv (PBSV) Total Current Liabilities (2010 - 2026)

Pharma-Bio Serv (PBSV) has reported Total Current Liabilities for 16 consecutive years, with $1.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities fell 41.29% year-over-year to $1.0 million; the trailing twelve-month figure through Apr 2026 stood at $1.0 million (down 41.29% YoY), and the FY2025 full-year result was $1.7 million, down 7.86% from the prior year.
• Total Current Liabilities declined to $1.0 million in Q2 2026 per PBSV's latest filing, from $3.3 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $3.7 million in Q1 2024 and bottomed at $1.0 million in Q2 2026.
• Historically, Total Current Liabilities has averaged $2.2 million across 5 years, with a median of $2.2 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Total Current Liabilities slumped 58.05% in 2022, then soared 87.53% in 2024.
• Over 5 years, Total Current Liabilities stood at $2.1 million in 2022, then rose by 2.18% to $2.2 million in 2023, then slipped by 12.37% to $1.9 million in 2024, then slipped by 7.86% to $1.7 million in 2025, then plunged by 39.89% to $1.0 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $1.0 million, $3.3 million, and $1.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.